Utility of a Risk Assessment Model in Predicting 30-day **Unplanned Hospital Readmission in Adult Patients Receiving Outpatient Parenteral Antibiotic Therapy**



Duke Antimicrobial Stewardship and Evaluation Team

Background


- Published 30-day all-cause readmission rates in patients receiving outpatient parenteral antibiotic therapy (OPAT) range from 6-26%.^{1,2,3}
- A 30-day unplanned readmission risk prediction model for OPAT patients in the United Kingdom (UK) was developed and validated with external cohorts totaling 2,500 patients.²
- Given the inherent differences in patient mix, acuity, and admission criteria in the United States (US) compared to the UK, there is a need for validity testing in local cohorts of patients in order to utilize this prediction model.

Methods

- Design: retrospective observational cohort study
- Study population: adult patients enrolled in the Duke University Health System (DUHS) OPAT program from 7/1/2019 – 2/1/2020
- Key Exclusion Criteria: Patients on dialysis and solid organ or hematopoietic stem cell transplant recipients
- Primary endpoint: 30-day unplanned readmission from index discharge
- Data Collection: parameters for the UK prediction model¹: age, number of hospitalizations in the prior 12 months, Charlson comorbidity score, mode of OPAT administration, source of infection and IV combination therapy
- Additional values tested included vancomycin use, OPAT delivered via skilled nursing facility, and history of IV drug abuse.
- Data analysis: discriminative ability of the model to predict 30-day unplanned readmission was validated and assessed using a scaled Brier score, C-index, calibration plot, and Hosmer-Lemeshow goodness of fit test⁴ Logistic regression was used to update the UK model.

Results			Figure 1. Receiver Operating Curve
Table 1. Cohort Demographics		Dula Cabart	(a) UK model for unplanned readmission (b) UK model with additional variables for unplanned readmission
Variable	UK Cohort n = 1073	Duke Cohort n = 470	
Age, mean (SD)	56 (17.5)	60.4 (16.1)	
Gender	00 (1710)	00.1 (10.1)	
Male	611 (56.9%)	282 (60%)	
Female	462 (43.1%)	188 (40%)	
Charlson comorbidity score, median	1 (0, 2)	3 (1, 5)	ensitivities and the second seco
(IQR)	. (0, –)		
Hospitalizations in prior 12 months, median (IQR)	0 (0, 1)	0 (0, 1)	
Indication for OPAT			
Skin/soft tissue	616 (57.4%)	33 (7%)	
Bone and joint	137 (12.8%)	276 (58.7%)	0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 1 – Specificity 1 – Specificity 1 – Specificity
Urogenital	70 (6.5%)	23 (4.9%)	Figure 2. Calibration of Model
Respiratory	45 (4.2%)	15 (3.2%)	(a) UK model for unplanned readmission (b) UK model with additional variables for unplanned readmission
Endovascular	45 (4.2%)	64 (13.6%)	
Other	160 (14.9%)	59 (12.6%)	0.9
Mode of OPAT			0.8
Home (self/caregiver)	105 (9.8%)	335 (71.3%)	
Infusion center	767 (71.5%)	0 (0%)	
Community nurse	201 (18.7%)	0 (0%)	
Skilled nursing facility	0 (0%)	135 (28.7%)	
Concurrent IV OPAT	81 (7.5%)	88 (18.7%)	
Vancomycin use	98 (9.1%)	170 (36.2%)	
Duration of OPAT, median (IQR)	7 (4, 14)	33 (19, 38)	0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Table 2. Cohort Outcomes 40			
Outcomes		Duke Cohort	0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
	n = 1073	n = 470	Predicted Probability Table 3. Model Performance
Readmissions within 30-day post-inde	X		Original UK model UK model with
discharge			additional variables
Any readmission	· · · · ·) 105 (22.3%)	Statistical Test aOR 95% p- aOR 95% p-
Planned readmission	22 (2.1%)	13 (2.8%)	CI value CI value
Unplanned readmission	123 (11.5%)		Discrimination, c- 0.52 (0.46, — 0.55 (0.49, —
Unplanned OPAT-related readmission	73 (6.8%)	56 (11.9%)	statistic 0.59) 0.62)
30-day unplanned OPAT-related			Hosmer-Lemeshow (df) 47.54 (8) - <0.001 7.04 (8) - 0.53
readmission			Scaled Brier score -0.07 0
Infection-related adverse effect	60 (83.3%)	X /	Calibration slope 0.06 (-0.28, — 1 (-0.39, —
Antibiotic-related adverse effect	7 (9.7%)	17 (30.3%)	0.38) 2.43)
IV access	3 (2.4%)	2 (3.5%)	Calibration-in-the-large -1.29 (-1.9, — 0 (-1.94, —
Other	3 (2.4%)	7 (12.5%)	-0.72) 1.97)
sd, standard deviation; IQR inter-quartile	range	aOR, adjusted odds ratio; CI, confidence interval; df, degrees of freedom	

Brenneman EK¹, Funaro JR¹, Dicks K¹, Yarrington M¹, Spivey J¹, Lee H-J¹, Erkanli A¹, Hung F¹, Drew R^{1,2} ¹Duke University Hospital, Durham, NC; ²Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC



Ethan.Brenneman@duke.edu DUMC Box 3089 **Durham, NC 27710** Phone: (919) 673-6944



Duke Center for

Antimicrobial Stewardship and Infection Prevention

Discussion

- Almost half of the unplanned readmissions were not OPAT related, but in further analysis of only OPAT related unplanned readmissions, the model still had poor predictive ability.
- Decreases in the performance of a model are common in external validation studies, often caused by differences in populations.
- Patients who self-administer antibiotics at home, seen more in the DUHS cohort, do not undergo the same monitoring as patients who receive antibiotics at an infusion clinic.

Limitations

- The retrospective nature of the study introduces the potential for reduced accuracy of recorded data.
- Patients who had readmissions outside of the electronic health record would have been missed.
- The determination of some secondary characteristics, was done via the discretion of the reviewing clinicians.

Conclusions

- The prediction model was not able to reliably discriminate the risk of 30-day unplanned readmission in DUHS patients receiving OPAT.
- The additional variables tested did not improve the predictive ability of the model.

References

- 1. Durojaiye, O.C., et al. Clin Microbiol Infect, 2019. 25(7): p. 905 e1-905.
- 2. Durojaiye, O.C., et al., J Antimicrob Chemother, 2021. 76(8): p. 2204-2212.
- 3. Huang, V., et al., BMC Pharmacol Toxicol, 2018. 19(1): p. 50.
- 4. Steverberg EWN, et al. Epidemiology. 2010 Jan;21(1):128-38.



